Sign in
CompletedPhase 2

A pilot single center, open label trial to assess the impact of doxycycline postexposure prophylaxis on antimicrobial resistance (SafeDoxyPEP trial)

Key facts

Who runs it
Institute Of Tropical Medicine
Where
Belgium1 site in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 2
People taking part
78 people enrolled
Started
13 Mar 2024
Ended
19 Jun 2025
Type of study
Interventional
Record updated
7 March 2024

Who can take part

Age
18 years and older
Sex
Men only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Able and willing to provide written informed consent
  • Age 18 years old or older
  • Eligible to take HIV PrEP
  • Male sex at birth

Who cannot take part

  • Use of any antibiotics in the previous 3 months
  • Currently using or planning to use anticoagulants based on vitamin K antagonism (warfarin, acenocoumarol, fenprocoumon)
  • Known contra-indications or allergy to doxycycline, gluten or lactose

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Assess if doxycycline PEP can result in reduced susceptibility to doxycycline in rectal E. coli on day 180

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A pilot single center, open label trial to assess the impact of doxycycline postexposure prophylaxis on antimicrobial resistance
Record updated
7 March 2024